The healthcare community is abuzz about Retatrutide 120 , a dual-action treatment showing remarkable benefits in preliminary research. This groundbreaking compound, a glucagon-like peptide-1 receptor agonist alongside a glucose-dependent insulinotropic molecule , appears to substantially decrease body weight and improve metabolic markers. Clinician